| Literature DB >> 33952277 |
Ramzi Shawahna1,2, Hiba Awawdeh3.
Abstract
BACKGROUND: Among all cancers, breast cancer is the most prevalent cancer and the leading cause of mortality among women in developing countries including Palestine. Community pharmacists are trusted and easily accessible healthcare providers who could be engaged in breast cancer health promotion. This study was conducted with the aim of exploring knowledge, attitudes, beliefs, and barriers toward breast cancer health promotion among community pharmacists in the Palestinian territories.Entities:
Keywords: Awareness; Breast cancer; Health services; Pharmacists; Screening; Signs and symptoms
Mesh:
Year: 2021 PMID: 33952277 PMCID: PMC8101222 DOI: 10.1186/s12913-021-06458-5
Source DB: PubMed Journal: BMC Health Serv Res ISSN: 1472-6963 Impact factor: 2.655
Sociodemographic and practice variables of the pharmacists who took part in the study (n = 200)
| Variable | n | % |
|---|---|---|
| < 30 | 100 | 50.0 |
| ≥ 30 | 100 | 50.0 |
| Male | 67 | 33.5 |
| Female | 133 | 66.5 |
| Never married | 74 | 37.0 |
| Married/divorced/widowed | 126 | 63.0 |
| BSc Pharmacy | 158 | 79.0 |
| Pharm.D | 18 | 9.0 |
| Postgraduate pharmacy education (MSc or PhD) | 24 | 12.0 |
| Palestine | 152 | 76.0 |
| Other | 48 | 24.0 |
| < 5 | 86 | 43.0 |
| 5 to < 10 | 43 | 21.5 |
| ≥ 10 | 71 | 35.5 |
| No | 180 | 90.0 |
| Yes | 20 | 10.0 |
| < 3 | 157 | 78.5 |
| ≥ 3 | 43 | 21.5 |
| Poor-Fair | 82 | 41.0 |
| Good-Excellent | 118 | 59.0 |
| < 40 | 80 | 40.0 |
| ≥ 40 | 120 | 60.0 |
| < 50 | 120 | 60.0 |
| ≥ 50 | 80 | 40.0 |
| < 20 | 128 | 64.0 |
| 20 %-49 | 38 | 19.0 |
| ≥ 50 | 34 | 17.0 |
| 1 | 96 | 48.0 |
| 2 or more | 104 | 52.0 |
| Rarely | 141 | 70.5 |
| Often | 59 | 29.5 |
| Rarely | 142 | 71.0 |
| Often | 58 | 29.0 |
| Rarely | 158 | 79.0 |
| Often | 42 | 21.0 |
| Rarely | 159 | 79.5 |
| Often | 41 | 20.5 |
BSc Bachelor of Science, Pharm.D Doctor of Pharmacy, MSc Master of Science, PhD Doctor of Philosophy
Responses of the community pharmacists on the 26-item knowledge test on the prevalence, risk factors, signs and symptoms, screening methods, and treatment of breast cancer
| Correct answer | Incorrect answer | Did not know | ||||||
|---|---|---|---|---|---|---|---|---|
| # | Question | Correct answer | n | % | n | % | n | % |
| 1 | Breast cancer is the most common form of cancer among women. | T | 178 | 89.0 | 8 | 4.0 | 14 | 7.0 |
| 2 | Breast cancer should not be of concern for patients younger than forty years of age. | F | 156 | 78.0 | 30 | 15.0 | 14 | 7.0 |
| 3 | Use of hormone replacement therapy is one of the risk factors for developing breast cancer. | T | 159 | 79.5 | 20 | 10.0 | 21 | 10.5 |
| 4 | Late onset menstrual period is one of the risk factors for developing breast cancer. | F | 68 | 34.0 | 58 | 29.0 | 74 | 37.0 |
| 5 | Old age increase risk of breast cancer. | T | 145 | 72.5 | 34 | 17.0 | 37 | 18.5 |
| 6 | There is no relationship between cigarette smoking and breast cancer. | F | 129 | 64.5 | 34 | 17.0 | 12 | 6.0 |
| 7 | Family history of breast cancer is a risk of breast cancer. | T | 176 | 88.0 | 12 | 6.0 | 12 | 6.0 |
| 8 | Use of oral contraceptive decrease risk of breast cancer. | F | 154 | 77.0 | 27 | 13.5 | 19 | 9.5 |
| 9 | There is no relationship between size of breast and risk of breast cancer. | F | 63 | 31.5 | 102 | 51.0 | 35 | 17.5 |
| 10 | Breastfeeding increase risk of breast cancer. | F | 180 | 90.0 | 8 | 4.0 | 12 | 6.0 |
| 11 | Nipple discharge can be a warning sign of breast cancer. | T | 159 | 79.5 | 19 | 9.5 | 22 | 11.0 |
| 12 | Painless breast lump under armpit is not sign of breast cancer. | F | 130 | 65.0 | 32 | 16.0 | 38 | 19.0 |
| 13 | Change in breast shape is a sign of breast cancer. | T | 171 | 85.5 | 15 | 7.5 | 14 | 7.0 |
| 14 | Pain in breast region and dimpling are signs of breast cancer. | T | 126 | 63.0 | 52 | 26.0 | 22 | 11.0 |
| 15 | Appropriate early screening for breast cancer reduces breast cancer mortality. | T | 185 | 92.5 | 5 | 2.5 | 10 | 5.0 |
| 16 | Breast self-examination is one of the methods that are used to detect the presence of breast cancer. | T | 184 | 92.0 | 7 | 3.5 | 9 | 4.5 |
| 17 | To detect the presence of breast cancer, women over the age of twenty and under the age of forty should do a breast self-examination at least once per year. | F | 44 | 22.0 | 136 | 68.0 | 20 | 10.0 |
| 18 | To detect the presence of breast cancer, women aged forty years and above should do a monthly breast self-examination, an annual clinical breast examination and a biannual mammogram. | F | 17 | 8.5 | 161 | 80.5 | 23 | 11.5 |
| 19 | Mammography is painful. | F | 100 | 50.0 | 49 | 24.5 | 51 | 25.5 |
| 20 | Mammography is safe. | T | 137 | 68.5 | 17 | 8.5 | 46 | 23.0 |
| 21 | Breast self-examination is recommended for women aged 35 and below and should be done once a month. | T | 90 | 45.0 | 59 | 29.5 | 51 | 25.5 |
| 22 | Total mastectomy is the surgical option of choice for patients diagnosed with early-stage breast cancer. | F | 99 | 49.5 | 73 | 36.5 | 28 | 14.0 |
| 23 | Patients with invasive breast cancer that is estrogen receptor positive should receive adjuvant endocrine therapy. | T | 119 | 59.5 | 17 | 8.5 | 64 | 32.0 |
| 24 | Tamoxifen is the adjuvant endocrine therapy of choice for premenopausal patients with invasive breast cancer. | T | 153 | 76.5 | 51 | 25.5 | 32 | 16.0 |
| 25 | The treatment of breast cancer is a long and painful process. | T | 117 | 58.5 | 35 | 17.5 | 11 | 5.5 |
| 26 | Treatment of breast cancer affects fertility. | F | 93 | 46.5 | 35 | 17.5 | 72 | 36.0 |
T true, F false
Responses of the pharmacists on the belief statements with regard to providing advice to patients on breast cancer
| Disagree | Neutral | Agree | |||||
|---|---|---|---|---|---|---|---|
| 1 | I should be involved in breast cancer health promotion activities in the pharmacy | 18 | 9.0 | 35 | 17.5 | 147 | 73.5 |
| 2 | Integrating breast cancer health promotion into my daily practice as a community pharmacist is important | 19 | 9.5 | 41 | 20.5 | 140 | 70.0 |
| 3 | I feel confident and prepared to provide breast cancer health promotion | 13 | 6.5 | 40 | 20.0 | 147 | 73.5 |
| 4 | Discussing breast cancer awareness with my female patients in the pharmacy is beneficial and can save their lives | 8 | 4.0 | 30 | 15.0 | 162 | 81.0 |
| 5 | Providing breast cancer counseling to my female patients in the pharmacy is my responsibility as a pharmacist | 39 | 19.5 | 41 | 20.5 | 119 | 59.5 |
| 6 | Distributing breast cancer educational materials is important in the pharmacy | 14 | 7.0 | 40 | 20.0 | 146 | 73.0 |
| 7 | It is important to discuss breast cancer with my female patients to encourage breast cancer early screening and detection | 7 | 3.5 | 42 | 21.0 | 151 | 75.5 |
| 8 | There is enough evidence to suggest that the pharmacist can influence patients to adopt breast cancer screening practices | 27 | 13.5 | 56 | 28.0 | 117 | 58.5 |
| 9 | Inviting healthcare professionals to provide breast cancer education to the female patients in the pharmacy is important | 29 | 14.5 | 56 | 28.0 | 115 | 57.5 |
| 10 | Providing breast cancer counseling to my patients can improve my professional state and increase my professional satisfaction | 9 | 4.5 | 39 | 19.5 | 152 | 76.0 |
| 11 | Providing breast cancer counseling is an effective use of my time | 11 | 5.5 | 60 | 30.0 | 129 | 64.5 |
| 12 | If I have access to patient education materials related to breast cancer, I am more likely to provide breast cancer health promotion to my female patients | 12 | 6.0 | 45 | 22.5 | 143 | 71.5 |
| 13 | Patients would like me as a pharmacist to counsel them on breast cancer screening and early detection | 29 | 14.5 | 58 | 29.0 | 113 | 56.5 |
| 14 | Patients appreciate my effort as a pharmacist to counsel them on breast cancer | 21 | 10.5 | 59 | 29.5 | 120 | 60.0 |
Barrier to providing breast cancer health promotion to patients visiting the pharmacy
| Disagree | Neutral | Agree | |||||
|---|---|---|---|---|---|---|---|
| 1 | Patients do not ask for breast cancer health promotion | 33 | 16.5 | 81 | 40.5 | 86 | 43.0 |
| 2 | Patients do not appreciate the pharmacist’s role as a breast cancer health promoter | 41 | 20.5 | 52 | 26.0 | 107 | 53.5 |
| 3 | Patients will be offended if I offer them breast cancer counseling | 42 | 21.0 | 26 | 13.0 | 132 | 66.0 |
| 4 | I am not reimbursed for providing breast cancer health promotion | 46 | 23.0 | 24 | 12.0 | 130 | 65.0 |
| 5 | Availability of enough personnel in the pharmacy to provide breast cancer health promotion to patients visiting the pharmacy | 34 | 17.0 | 30 | 15.0 | 136 | 68.0 |
| 6 | Having enough time to provide breast cancer health promotion to patients visiting the pharmacy | 18 | 9.0 | 60 | 30.0 | 122 | 61.0 |
| 7 | Having enough space to provide breast cancer health promotion to patients visiting the pharmacy | 27 | 13.5 | 49 | 24.5 | 124 | 62.0 |
| 8 | Have access to breast cancer educational materials | 42 | 21.0 | 63 | 31.5 | 95 | 47.5 |
| 9 | The pharmacy manager does not support my role as a breast cancer health promoter | 93 | 46.5 | 24 | 12.0 | 83 | 41.5 |
Associations between sociodemographic and practice variables of the pharmacists and scoring 50 % or more in the knowledge test
| Knowledge score | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| < 30 | 100 | 50.0 | 23 | 11.5 | 77 | 38.5 | 8.23 | 0.006 | -0.20 | 0.004 |
| ≥ 30 | 100 | 50.0 | 42 | 21.0 | 58 | 29.0 | ||||
| Male | 67 | 33.5 | 38 | 19.0 | 29 | 14.5 | 26.93 | < 0.001 | 0.37 | < 0.001 |
| Female | 133 | 66.5 | 27 | 13.5 | 106 | 53.0 | ||||
| Never married | 74 | 37.0 | 18 | 9.0 | 56 | 28.0 | 3.58 | 0.063 | -0.13 | 0.059 |
| Married/divorced/widowed | 126 | 63.0 | 47 | 23.5 | 79 | 39.5 | ||||
| BSc Pharmacy | 158 | 79.0 | 58 | 29.0 | 100 | 50.0 | 6.08 | 0.045 | 0.17 | 0.014 |
| Pharm.D | 18 | 9.0 | 3 | 1.5 | 15 | 7.5 | ||||
| Postgraduate pharmacy education (MSc or PhD) | 24 | 12.0 | 4 | 2.0 | 20 | 10.0 | ||||
| Palestine | 152 | 76.0 | 40 | 20.0 | 112 | 56.0 | 11.04 | 0.001 | -0.23 | 0.001 |
| Other | 48 | 24.0 | 25 | 12.5 | 23 | 11.5 | ||||
| < 5 | 86 | 43.0 | 23 | 11.5 | 63 | 31.5 | 6.27 | 0.045 | 0.15 | 0.030 |
| 5 to < 10 | 43 | 21.5 | 11 | 5.5 | 32 | 16.0 | ||||
| ≥ 10 | 71 | 35.5 | 31 | 15.5 | 40 | 20.0 | ||||
| No | 180 | 90.0 | 61 | 30.5 | 119 | 59.5 | 1.58 | 0.314 | 0.09 | 0.210 |
| Yes | 20 | 10.0 | 4 | 2.0 | 16 | 8.0 | ||||
| < 3 | 157 | 78.5 | 49 | 24.5 | 108 | 54.0 | 0.55 | 0.467 | -0.05 | 0.459 |
| ≥ 3 | 43 | 21.5 | 16 | 8.0 | 27 | 13.5 | ||||
| Poor-Fair | 82 | 41.0 | 28 | 14.0 | 54 | 27.0 | 0.17 | 0.759 | 0.03 | 0.680 |
| Good-Excellent | 118 | 59.0 | 37 | 18.5 | 81 | 40.5 | ||||
| < 40 | 80 | 40.0 | 26 | 13.0 | 54 | 27.0 | 0.00 | 1.000 | 0.00 | 1.000 |
| ≥ 40 | 120 | 60.0 | 39 | 19.5 | 81 | 40.5 | ||||
| < 50 | 120 | 60.0 | 39 | 19.5 | 81 | 40.5 | 0.00 | 1.000 | 0.00 | 1.000 |
| ≥ 50 | 80 | 40.0 | 26 | 13.0 | 54 | 27.0 | ||||
| < 20 % | 128 | 64.0 | 39 | 19.5 | 89 | 44.5 | 1.08 | 0.592 | 0.05 | 0.494 |
| 20-49 % | 38 | 19.0 | 15 | 7.5 | 23 | 11.5 | ||||
| ≥ 50 % | 34 | 17.0 | 11 | 5.5 | 23 | 11.5 | ||||
| 1 | 96 | 48.0 | 31 | 15.5 | 65 | 32.5 | 0.00 | 1.000 | 0.00 | 0.952 |
| > 1 | 104 | 52.0 | 34 | 17.0 | 70 | 35.0 | ||||
| Rarely | 141 | 70.5 | 44 | 22.0 | 97 | 48.5 | 0.37 | 0.620 | -0.04 | 0.548 |
| Often | 59 | 29.5 | 21 | 10.5 | 38 | 19.0 | ||||
| Rarely | 142 | 71.0 | 45 | 22.5 | 97 | 48.5 | 0.15 | 0.741 | -0.03 | 0.704 |
| Often | 58 | 29.0 | 20 | 10.0 | 38 | 19.0 | ||||
| Rarely | 158 | 79.0 | 50 | 25.0 | 108 | 54.0 | 0.25 | 0.711 | -0.04 | 0.619 |
| Often | 42 | 21.0 | 15 | 7.5 | 27 | 13.5 | ||||
| Rarely | 159 | 79.5 | 52 | 26.0 | 107 | 53.5 | 0.01 | 1.000 | 0.01 | 0.904 |
| Often | 41 | 20.5 | 13 | 6.5 | 28 | 14.0 | ||||
BSc Bachelor of Science, Pharm.D Doctor of Pharmacy, MSc Master of Science, PhD Doctor of Philosophy
Multivariate regression analysis of association between sociodemographic and practice variables with scoring 50 % or more in the knowledge test
| 95 % CI for OR | |||||||
|---|---|---|---|---|---|---|---|
| < 30 | 0.86 | 0.61 | 1.97 | 0.160 | 2.36 | 0.71 | 7.80 |
| ≥ 30 | Reference category | ||||||
| Male | Reference category | ||||||
| Female | 1.55 | 0.38 | 17.02 | < 0.001 | 4.73 | 2.26 | 9.89 |
| BSc Pharmacy | Reference category | ||||||
| Pharm.D | 1.34 | 0.70 | 3.68 | 0.055 | 3.82 | 0.97 | 15.03 |
| Postgraduate pharmacy education (MSc or PhD) | 0.42 | 0.89 | 0.22 | 0.640 | 1.52 | 0.26 | 8.70 |
| Palestine | 0.35 | 0.44 | 0.65 | 0.421 | 1.42 | 0.60 | 3.35 |
| Other | Reference category | ||||||
| < 5 | Reference category | ||||||
| 5 to < 10 | -0.82 | 0.67 | 1.52 | 0.218 | 0.44 | 0.12 | 1.63 |
| ≥ 10 | -0.15 | 0.52 | 0.08 | 0.782 | 0.87 | 0.31 | 2.42 |
BSc Bachelor of Science, Pharm.D Doctor of Pharmacy, MSc Master of Science, PhD Doctor of Philosophy, OR Odds ratio, SE standard error.